BHV BHV
Company Profile ↓Company Overview
BHV (BHV) is a publicly traded company listed on with a market capitalization of $19.81M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Maintains a net profit margin of 75.3%.
Carries low leverage with a debt-to-equity ratio of 0.01.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -22.7%, profit CAGR -30.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -22.65% |
| 1 Year: | - |
Compounded Profit Growth
| 5 Years: | -30.85% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +29.25% |
| 6 Months: | +18.86% |
| 3 Months: | +1.66% |
| 1 Month: | -1.15% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)44.95 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Excellent profit margin of 75.3%.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -22.7% CAGR over 5 years.
- Earnings shrank at -30.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|
| Revenue | 1.53M | -683.94K | 917.17K | - |
| Cost of Revenue | - | - | - | - |
| Gross Profit | - | - | - | - |
| Operating Expenses | 89.07K | 127.69K | 133.39K | - |
| Operating Income | - | - | - | - |
| EBITDA | - | - | - | - |
| Interest Expense | 158.39K | 489.67K | 524.21K | - |
| Pretax Income | 1.44M | -811.63K | 690.48K | - |
| Tax Provision | - | - | - | - |
| Net Income | 1.44M | -811.63K | 690.48K | - |
| Diluted EPS | 0.90 | -0.50 | - | -0.95 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 |
|---|---|---|---|
| Total Assets | 41.90M | 34.65M | 31.51M |
| Current Assets | - | - | - |
| Cash & Equivalents | - | - | - |
| Inventory | - | - | - |
| Receivables | 376.08K | 280.34K | 289.87K |
| Total Liabilities | 16.57M | 14.69M | 11.70M |
| Current Liabilities | - | - | - |
| Long Term Debt | - | - | - |
| Total Debt | - | 2.31K | 1.70K |
| Total Equity | 25.33M | 19.96M | 19.82M |
| Shares Outstanding | 1.61M | 1.60M | 1.59M |
Cash Flows (Annual)
Figures in USD.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 |
|---|---|---|---|
| Operating Cash Flow | 868.06K | 1.72M | 2.78M |
| Investing Cash Flow | - | - | - |
| Financing Cash Flow | -868.06K | -1.76M | -2.77M |
| Capital Expenditure | - | - | - |
| Free Cash Flow | 868.06K | 1.72M | 2.78M |
| Net Change in Cash | 0 | -39.00K | 18.00K |
Ratios (Annual)
Figures in %.
| Metric | Aug 2021 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | - | - | - | - |
| Net Margin % | 94.2% | 118.7% | 75.3% | - |
| ROE % | 5.7% | -4.1% | 3.5% | - |
| ROCE % | - | - | - | - |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BHV
Did Biohaven’s Kv7 Deal With SK Biopharmaceuticals Just Reshape BHVN’s Risk And Funding Profile? - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi1wFBVV95cUxPNkZPVG5vS1ZRdTZaUjI5S2lhYWU4Y2NJdG1IcEU1Zndob01BbU1qY1lheWhUbDZhOFRXbU5lS1VSc2hpMURic1RlYXFKM3FCV2dCclR3ZVpqNEtaZVhGZlJ2eV9wbEtKMXBZOVgxVHFDejRqSE83MzhKV21keDh5Rk5aSGVsTXlzbFh0Qz…
Behavioral Patterns of BHV and Institutional Flows - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT3BTaFUyUE9TdWdlVlpZSjVUZUREZTRYVFZIVHQxRDRwaXRFVUFUYWh5M2pDcEtaUGdUdk10M0VmWVpSQkx3OGd0b0wxQUZNVW05REdnZ2FlRFJhV1lBblptUlNUSE1oaC1EOFcwTHRkMkM4cEF2RHgzekZHV3dqUGthYmhzQUM4eDJyRj…
BlackRock Virginia Municipal Bond Trust (BHV) Dips 0.74% to $12.70 Amid Muni CEF Rate Uncertainty - Institutional Sentiment - vinanet.vn
<a href="https://news.google.com/rss/articles/CBMizAFBVV95cUxPRkxSUzd6aXo2dEozUzk4TGs5eTVtdTNFSkZNVk1TbGJ3N244UXlZQzRqZ2VBREtxNTEzZXFyVEdzcUszRGlXcWo3UkkyWmJXWkN6b3pEU2l6Mjlta3U3RmJfRmJUWDktRUZCcnc5eHdLcVFCN095TkxKNFlrY096d1pKMGJ1b21xSEFRVX…
BlackRock Virginia MBT (BHV) Peer Comparison – Compare with Others - Value Research
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxPQWtJQkh5QUd6bWFaWlI2TTVQd1hrQk1vSV9JaFNTOE5rN3FyNHpxMk9DYXhwaTNwRjJJdC1jUmJhUGRQVGVqVGx3OUMwY1p5eWY1N1JtU0MwUm9CSDJvcklFV0NmNTdZY0M4T1ctbjNEaGFJLUE3M3ZOZXp2ZTY0YnJmQ0prd3RiaEtNal…
Biohaven’s BHV-1530 targets FGFR3 tumors with or without alterations - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQc3BpaURSUVZMM2w3dmh4WnJ3OEV6dmdZRXc5VlpyT2ZxMHF5SG9zUzdJNWllS19DYzFoMjRzRllGVnBuZzZ5MUxRcGs3RmhNdVdfdWJXTTNUQk9TU21FbXBoYUdZMzQyUTlsQS1LMDEzajNmamF1ckFFU0ZPVTJWZk0taGhpSGNJa293bn…
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo Data - What's Changed - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTE96SUZwdXpYZFdNRFphQTlWUjg3c2RicHNNbklBa0MxNGM0UVM3RmI5TzRST2tXTkI3NXQxTDhOVGxmeWZzaGp4aDB1MW9peVFhVlNlZ0dGSFlTbjJXaTZ6X2lkN2gxVmZ5R09mOEhDaGF4b19IS0hr?oc=5" target="_blank">Biohave…
BHV — Frequently Asked Questions
What is the current share price of BHV?
As of 2026-09-07 16:24 PDT, BHV trades at $12.47 on NASDAQ/NYSE. Its 52-week range is $9.65 to $13.15.
What is the market capitalisation of BHV?
BHV has a market capitalisation of $19.81M on NASDAQ/NYSE.
What is the P/E ratio of BHV?
BHV trades at a trailing price-to-earnings (P/E) ratio of -13.13. Its price-to-book (P/B) ratio is 1.00.
What is the return on equity (ROE) of BHV?
BHV has a return on equity (ROE) of 3.48%.
Is BHV a good stock to buy?
This page provides a data-driven analysis of BHV, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.